New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA ® (canagliflozin) are Consistent Across Various Levels of Kidney Function

Analysis shows consistent renal and cardiovascular benefit when treated with INVOKANA ® even when patients had moderate to severe renal deficiency INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKDData announcemen t comes after recent news of the company’s commercial partnership with Vifor Pharma, leader in nephrology, to jointly commercialize the INVOKANA® DKD indication in the United States
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news